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The development of drug resistance is one of the major obstacles in cancer chemotherapy (1) . One of the most intensely scrutinized mechanisms is that of multidrug resistance (MDR), defined as resistance to a variety of different lipophilic compounds (2) (3) (4) . Amplification of the multidrugresistance gene (mdr-1) and resultant overexpression of the P-glycoprotein are thought to be chiefly responsible for development of MDR in many (5) but not all systems (6, 7) . The P-glycoprotein is a 170-kDa transmembrane protein that functions as an energy-dependent efflux pump serving to decrease accumulation of structurally unrelated cytotoxic agents in the intracellular milieu (8) .
The Fos oncoprotein has been implicated in a variety of cellular processes, including DNA synthesis, apoptosis, and drug resistance (9) (10) (11) . Fos is thought to mediate its various effects through transcriptional activation after interaction with the Jun protein to form the AP-1 complex (12) (13) (14) . Our previous studies have implicated c-fos overexpression in resistance to a number of chemotherapeutic agents, including cisplatin, 5-fluorouracil, and 3'-azido-3'-deoxythymidine (AZT), none of which is included in the MDR family (15, 16) . We demonstrated that Fos may regulate DNA synthesis and repair pathways by upregulating transcription of a number of AP-1 responsive genes-namely, thymidylate synthase (17) and topoisomerase I (15) . A ribozyme that cleaved c-fos mRNA was shown to reverse resistance to cisplatin, 5-fluorouracil, AZT, and camptothecin and to reduce expression of enzymes involved in synthesis ofDNA and its precursors (15) .
Interestingly, the upstream promoter of the mdr-1 gene contains an AP-1 binding site (18 cDNA, human mdr-1 (no. 39839) cDNA, and the pMMV-fos plasmid were obtained from American Type Culture Collection (Rockville, MD). cDNAs were isolated as described (15) .
[G-3H]Actinomycin D was obtained from Moravek Biochemicals (La Brea, CA).
A2780 Cels. The drug-sensitive human ovarian carcinoma cell line A2780S was obtained from R. Ozols (Fox Chase Cancer Center, Philadelphia), and the A2780AD-resistant cell line was isolated by weekly administrations ofcontinuous exposure (for 72 hr) to actinomycin D for 9 months. In general, the cells were transferred to new RPMI 1640 medium on a weekly basis as described (15) . The A2780AD cell line had a stable resistance to actinomycin D when grown in the absence of drug. For cytotoxicity determinations, 100 cells were inoculated in 60-mm tissue culture dishes. Twenty-four hours later, the cells were treated with cancer chemotherapeutic agents. The colonies were washed 6 days later, fixed in methanol stained with Giemsa dye, and assayed.
A2780ADpfosRz cells were pretreated with 0.5 pM dexamethasone for 24 hr before addition of the chemotherapeutic agents (15) . The EC50 represents the drug concentration that inhibited 501% of the cell growth in the various cell lines.
Phlamid Constution. The anti-fos ribozyme was cloned into the plasmid pMAMneo (Clontech) as described (15) . Primers for screening cell lines for the presence of pMAMneofosRz plasmid were previously published (15 transcriptase (RT)-PCR, used to detect ribozyme expression, was performed with 100 ng ofmRNA from various A2780 cell lines, primers for synthesis of the ribozyme construct, and a protocol provided by Perkin-Elmer/Cetus. The amplification, blotting, and hybridization procedures were performed as described (20) . The sequences for primers and the probe used to detect anti-fos ribozyme expression were previously published (15) . The quantification of the RT-PCR assay was performed by the concurrent use of known mRNA quantities in the amplification reaction.
Northern Analysis. RNA isolation, electrophoresis, hybridization, and densitometric analysis (AMBIS Systems) were performed as described (23 (24) . The uptake over a period of 120 min was quantified as follows: at each time point, cells were washed three times with ice-cold Dulbecco's phosphate-buffered saline (PBS; without CaCl2 and MgCl2; GIBCO). The radioactive material associated with these cells was solubilized by incubating the cells overnight in 1 M NaOH. Aliquots were saved for protein determination, and the remainder was neutralized with 1 M HCl. The radioactivity was determined by scintillation spectrometry as described (24) .
RESULTS
Parental A2780S human ovarian carcinoma cells were grown in the presence of actinomycin D weekly for 9 months, and the resultant subline (denoted A2780AD) was shown to be 16.6-fold more resistant to actinomycin D, with an ECso of 10.0 nM, than were A2780S cells (EC5o, 0.6 nM; Table 1 ). A2780AD cells were demonstrated to exhibit the MDR phenotype, with cross-resistance to vincristine, doxorubicin, and etoposide (VP-16) ( Table 2) . Associated with this resistance spectrum was a morphological change to cuboidal cells when compared to the spindle-shaped drug-sensitive A2780S cells (Fig. 1 ). There was no increased resistance to methotrexate, a drug not in the MDR family.
Expression of the MDR phenotype was concomitantly associated with overexpression of the mdr-1 gene (Fig. 1) , without the presence of mdr-1 gene amplification (data not shown). Moreover, [3Hlactinomycin D uptake was shown to be significantly reduced in A2780AD cells (Fig. 2) , corresponding to overexpression of mdr-1, which encodes the P-glycoprotein efflux pump. A2780AD cells were studied for expression of genes previously implicated in signal transduction and drug resistance pathways. Interestingly, A2780AD cells also overexpressed the protooncogenes c-fos and c-jun and, to a lesser degree, topoisomerase I and the mutant form of the tumor suppressor gene p53 (Fig. 1) .
Elevated c-fos has been previously demonstrated in cisplatin-resistant cell lines (22) , and expression of an anti-fos ribozyme reversed cisplatin resistance in A278ODDP cells (15) . To investigate whether the anti-fos ribozyme could also modulate MDR, the dexamethasone-inducible plasmid pMAMneofosRz (15) Fig. 3A ). This target site resides between two ATPbinding sites, with possibly important implications for P-glycoprotein function (8) . The resultant A2780ADpmdrRz cells were shown to express the anti-mdr ribozyme by RT-PCR (Fig. 1) . mdr-1 gene expression was reduced by >90o in A2780ADpmdrRz cells when compared to A2780AD cells (Fig. 1) . Demonstration of ribozyme cleavage was achieved by Northern analysis of mdr-1 polyadenylylated mRNA. In Using 10 pg of mRNA, however, a strong band was detected beginning at 2.6 kb, the approximate length of the mdr-1 transcript after ribozyme cleavage (Fig. 3) . After several weeks ofin vitro propagation, the anti-mdr ribozyme restored actinomycin D cytotoxicity with an EC50 of0.9 nM (Table 1 ). In contrast, there was no change in the EC5o of actinomycin D in A2780AD cells transfected with the pHPApr-1 neo vector only (Table 1) . Morphologically, A2780ADpmdrRz cells had the spindly appearance of A2780S cells (Fig. 1) . Concomitantly, labeled actinomycin D uptake was present at levels similar to that of A2780S cells (Fig. 2) . The resistance panel to other agents in the MDR phenotype was significantly altered in a manner similar to that of the A2780ADpfosRz cells, with near-complete restoration of sensitivity to vincristine, doxorubicin, and VP-16 (Table 2 ). There was no change in the ECQo of methotrexate in these studies (Table 2) .
Finally, Northern analysis revealed decreased mRNA for c-fos and p53 (but not c-jun) in A2780ADpmdrRz cells when compared to drug-resistant A2780AD cells (Fig. 1) .
In comparing the effects of the two ribozymes, a disparate pattern of resensitization to chemotherapeutic agents was observed upon plasmid transfection. The anti-fos ribozyme restored sensitivity to actinomycin D within 3 weeks after withdrawal of G418 (Fig. 4) . In contrast, A2780ADpmdrRz cells initially were resistant to actinomycin D. After 17 weeks of propagation in culture, the EC50 gradually reached sensitive levels, similar to that found in A2780ADpfosRz cells. When the sublines were re-treated with actinomycin D weekly for 2 weeks, A2780ADpfosRz cells were 3-fold more resistant to actinomycin D, and the ECQo returned to baseline in 3 weeks. In A2780ADpmdrRz cells, however, the drug rechallenge resulted in an 8-fold increased resistance. This resistance decreased more slowly than in A2780ADpfosRz cells, such that by week 20 a 4-fold level of resistance still remained (Fig. 4) . As a control, A2780AD cells had a stable resistance to actinomycin D over a 5-month period (Fig. 4) . transfected with and overexpressing c-fos exhibit MDR; and (iii) an anti-fos ribozyme reversed the MDR phenotype in A2780AD cells. Our data utilized morphological, pharmacological, and molecular analysis to better define this association. Fos has been previously shown to play a role in resistance to agents not within the MDR family, such as cisplatin, AZT, and 5-fluorouracil (15 Expression of mdr-1 has been previously demonstrated to be modulated by the Ha-ras and p53 genes in chloramphenicol acetyltransferase assays (25, 26) . These studies used cotransfection assays with the downstream promoter cloned into the chloramphenicol acetyltransferase-containing vector in order to assess promoter responsiveness to these genes. We analyzed gene expression in a cellular environment and in a time-dependent fashion after ribozyme induction by dexamethasone. These results support the previous finding linking mutant p53 expression with that of mdr-1. They extend that concept by demonstrating that diminished p53 and mdr-1 mRNA after anti-fos ribozyme action may contribute to reversal of the MDR phenotype. These studies also suggest an association between expression of c-fos and p53. Moreover, a putative connection exists in signal transduction between Ha-ras and c-fos, as fos antisense has been shown to abrogate Ha-ras-mediated activation of other genes such as collagenase and transin (27, 28) . Intriguingly, Ha-ras gene expression was also reduced in anti-fosRz-treated cells (data not shown). Finally, c-jun expression is also linked to Ha-ras-directed pathways, as the Ha-ras gene product potentiates c-jun activity by phosphorylating Jun (29) . Collectively, these observations describe the existence of an intricate cellular network of cross-signaling involving transcriptional and posttranslational regulation. These pathways appear to be activated in response to a diverse array of stimuli, such as growth factors, tumor promoters, and cancer chemotherapeutic agents.
As mentioned earlier, the upstream regulatory sequences of the mdr-1 gene contain an AP-1 binding site (30) . Even though this region is not the dominant promoter for mdr-1 in all circumstances, it has been shown to be required for full promoter activity in Chinese hamster ovary cells (18) . In addition, the AP-1-containing promoter may be active in cell lines that overexpress mdr-1 RNA without gene amplification (31, 32) , which is precisely the situation encountered in A2780AD cells. Therefore, downregulation of mdr-1 RNA after anti-fos ribozyme action is part of the cascade effecting reversal of the MDR phenotype.
Our results also indicate the efficacy of an anti-MDR ribozyme in reversing the MDR phenotype. This parallels the use ofanti-MDR ribozymes to suppress mdr-1 mRNA in other model systems (33, 34) . With extremely high levels of drug resistance, other mechanisms of resistance may be activated and may even predominate. It would be intriguing to use the anti-fos ribozyme in cell lines in which suppressing mdr-1 expression is insufficient to restore drug cytotoxicity or in which multidrug-resistant-related protein is overexpressed (7) .
Interestingly, A2780ADpmdrRz cells also displayed diminished gene expression of c-fos, topoisomerase I, and p53 ( Fig.   1 ). However, it must be noted that those experiments represent a one-time measurement, since the pHj3Apr-1 neo plasmid containing the anti-MDR ribozyme uses the -actin promoter to drive constitutive expression of the ribozyme and is not inducer driven as shown with A2780ADpfosRz cells. Therefore, the reduced gene expression observed may be less a result of direct effects on transcriptional regulation ofthese genes and more a reflection of selection pressures on a cell subline displaying the drug-sensitive phenotype and containing normal levels of the mdr-1 gene product.
Finally, the differential pattern of drug sensitivity between the two ribozymes may offer mechanistic explanations for action of the two genes in drug resistance. The observation that the anti-fos ribozyme reversed actinomycin D resistance more quickly may suggest that c-fos may modulate genes other than mdr-1 which also contribute to the MDR phenotype. One such candidate is topoisomerase I, also implicated in atypical MDR, in which mdr-1 gene expression is unperturbed (6) . Our studies demonstrate that anti-fos ribozyme action has also resulted in reduced expression of topoisomerase I.
In conclusion, the data presented here demonstrate the efficacy of an anti-fos ribozyme in reversing the MDR phenotype, while reducing expression of mdr-1, c-jun, p53, and topoisomerase I. The anti-fos ribozyme was equally, if not more, effective than the anti-MDR ribozyme. This suggests the primacy of c-fos in many drug-resistance processes.
